Avandia / Rosiglitazone
Avandia, also known as rosiglitazone, is a drug used to treat type II diabetes. Avandia is a thiazolidinedione class drug manufactured by Glaxo Smith Kline Pharmaceuticals. The drug assists the body in utilizing insulin. The FDA approved Avandia in 1999.
Avandia is similar to Rezulin, another type II thiazolidinedione class diabetes drug that was withdrawn from the market because of its tendency to cause liver failure. There is some concern that side effects of Avandia for diabetes may include an increased risk of developing liver problems.
In February 2001 the FDA required Glaxo to change the Avandia side effects label to reflect the increased risk of cardiac failure in patients combining Avandia with insulin. Studies indicate that concurrent use of Avandia and insulin can result in fluid-overload disease, which in turn may lead to heart failure and death.
In September 2003, doctors at the University of Texas Southwestern Medical Center at Dallas confirmed reports of heart problems in patients taking Avandia. According to the researchers' data, Avandia and Actos may cause heart failure and a buildup of fluid in the lungs.
An October 2003 study published in the journal Endocrinology reveals Avandia's link to a significant risk of bone loss. Researchers at the University of Arkansas for Medical Sciences report that in a laboratory study Avandia caused a decrease in bone density in patients.
See your doctor if you have experienced serious side effects associated with Avandia or are searching for Avandia alternatives. In addition, it may be important to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.
Attorneys associated with InjuryBoard.com will evaluate your case free of charge. In addition, you will not pay any fees unless your attorney recovers money for you. Please click on the free Ask An Attorney button to take advantage of this valuable service.
-- Article Courtesy of InjuryBoard.com
More ...
.